News of the WeekGene Therapy

What to Do When Clear Success Comes With an Unclear Risk?

See allHide authors and affiliations

Science  18 Oct 2002:
Vol. 298, Issue 5593, pp. 510-511
DOI: 10.1126/science.298.5593.510

You are currently viewing the summary.

View Full Text

Log in to view the full text

Log in through your institution

Log in through your institution


An expert panel, meeting in an emergency session last week, urged the U.S. Food and Drug Administration to lift a hold it had placed on three gene therapy trials after a patient treated with gene therapy in France developed cancer. The panel made the recommendation after concluding that the cancer was almost certainly caused by the gene therapy.